OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Artificial intelligence's processing power creates more accurate reports for improved drug safety.
Lipids aren’t the only important ingredients influencing stability and in vivo performance.
PAT is crucial to process control and real-time release in continuous manufacturing of solid-dosage drugs.
The trends shaping the growth of the biologics outsourcing industry demand attention.
Point of Care and Patient Manufacturing
April 01, 2023
Contract testing services demonstrate a major increase in the speed and efficiency of testing using new testing methods and technologies.
March 31, 2023
FDA has approved Evkeeza for young children with homozygous familial hypercholesterolemia.
March 30, 2023
Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.
CDMO Exothera and biotech company Remedium are joining forces to scale up the manufacturing process for Remedium’s lead gene therapy candidate for treating osteoarthritis.
Takeda plans to build a new facility in Osaka, Japan, for the manufacture of plasma-derived therapies.
Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel.
Pierre Luzeau, CEO of Seqens, discusses Seqen's commitment to sustainability and how one can work toward it within their own company.
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
March 29, 2023
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry